Increased use of minimally invasive non-endoscopic tests for Barrett's esophagus screening
(American College of Physicians) The authors of a new commentary from Mayo Clinic suggest that more extensive use of minimally invasive non-endoscopic tests for Barrett's esophagus (BE) screening could impact early detection and prevention of esophageal adenocarcinoma (EAC), a particularly deadly form of cancer. This is important because BE, the only known precursor to esophageal cancer, is often asymptomatic. Their commentary is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 3, 2021 Category: Infectious Diseases Source Type: news
Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
TUESDAY, April 20, 2021 -- Opdivo (nivolumab) is now approved for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the U.S. Food and Drug Administration announced Friday.
The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 20, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021
Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1
U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2021 Category: Drugs & Pharmacology Source Type: news
Pancreatic Cancer Surveillance in High-Risk: No Better Outcomes Pancreatic Cancer Surveillance in High-Risk: No Better Outcomes
Surveillance of people at high hereditary risk for pancreatic ductal adenocarcinoma can lead to diagnosis at an earlier stage, but as yet there is no clear survival benefit, a new study suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 16, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news
FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 16, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
What Is Lung Adenocarcinoma?
Title: What Is Lung Adenocarcinoma?Category: Diseases and ConditionsCreated: 4/16/2021 12:00:00 AMLast Editorial Review: 4/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 16, 2021 Category: Cancer & Oncology Source Type: news
AI System Beats Endoscopists for Detecting Neoplasia in Barrett's AI System Beats Endoscopists for Detecting Neoplasia in Barrett's
The deep-learning system is designed to reduce the rate of failed detection of high-grade dysplasia and early adenocarcinoma in patients undergoing surveillance by gastrointestinal endoscopists.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 2, 2021 Category: Internal Medicine Tags: Gastroenterology News Source Type: news
Variations in a gene and a protein aggravate the prognosis of one gastric tumor
(Universidad Complutense de Madrid) More than a million people worldwide were diagnosed with stomach cancer in 2018, the fifth most prevalent cancer. The most common gastric tumor is gastric adenocarcinoma, originating in the gastric mucosa. A research team led by the University Complutense of Madrid in Spain has identified 2 biomarkers that help predict the risk of developing the disease, as well as a poorer prognosis: polymorphisms-variations-of the transforming growth factor B1 (TGFB1) gene and the TGFB1 protein. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2021 Category: Cancer & Oncology Source Type: news
PET/MRI biomarkers guide personalized treatment for patients with pancreatic cancer
Positron emission tomography (PET)/MRI has changed how Mayo Clinic specialists treat patients with pancreatic cancer. Mayo Clinic pioneered the use of PET/MRI to manage pancreatic cancer. Now a new study by Ananya Panda, M.B.B.S., and colleagues systematically evaluates the strengths of PET/MRI for pancreatic ductal adenocarcinoma (PDAC). In less than five years, Mayo's PET/MRI practice [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 4, 2021 Category: Databases & Libraries Source Type: news
FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
Phase I/II Clinical Trial to Be Initiated in First Quarter 2021
CAMBRIDGE, Mass., Feb. 23, 2021 -- (Healthcare Sales & Marketing Network) -- Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on i... Biopharmaceuticals, Oncology, FDA Elicio Therapeutics, Amphiphile, KRAS, pancreatic ductal adenocarcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2021 Category: Pharmaceuticals Source Type: news
FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Is Intestinal Adenocarcinoma an Aggressive Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news
Is Adenocarcinoma of the Lung an Aggressive Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news
New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings showed robu...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
